Nanoparticles for Oral Delivery of Insulin

Advances in Predictive, Preventive and Personalised Medicine

Volumn 4, Issue , 2013, Pages 109-125

  Ribeiro, Antonio J ^a   Seiça, Raquel ^b   Veiga, Francisco ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Gastrointestinal epithelium; Insulin; Nanoparticle; Oral bioavailability; Personalized medicine; Therapeutic dose

Indexed keywords

INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; NANOPARTICLE;

ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE EPITHELIUM; MEMBRANE TRANSPORT; NANOENCAPSULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PORTAL VEIN BLOOD FLOW; PRIORITY JOURNAL; STOMACH SECRETION; TRANSCYTOSIS;

EID: 84905220072     PISSN: 22113495     EISSN: 22113509     Source Type: Book Series    
DOI: 10.1007/978-94-007-6010-3__4     Document Type: Article

References (80)

1. WHO (2012) Diabetes. Fact sheet Ni{dotless}312.
2. Müller G (2010) Oral protein therapy for the future-transport of glycolipid-modified proteins: vision or fiction? Pharmacology 86: 92-116.
3. Arbit E (2004) The physiological rationale for oral insulin administration. Diabetes Technol Ther 6: 510-517.
4. Langer R, Peppas NA (2003) Advances in biomaterials, drug delivery, and bionanotechnology. AIChE J 49: 2990-3006.
5. Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F (2006) Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems. Nanomedicine 2: 53-65.
6. American Diabetes Association (2010) Standards of medical care in diabetes-2010. Diabetes Care 33: S11-S61.
7. Meneghini L (2008) Demonstrating strategies for initiation of insulin therapy: matching the right insulin to the right patient. Int J Clin Pract 62: 1255-1264.
8. Freeman JS (2009) Insulin analog therapy: improving the match with physiologic insulin secretion. J Am Osteopath Assoc 109: 26-36.
9. Gerich JE (2002) Novel insulins: expanding options in diabetes management. Am J Med 113: 308-316.
10. Silva CM, Ribeiro AJ, Figueiredo IV, Goncalves AR, Veiga F (2006) Alginate microspheres prepared by internal gelation: development and effect on insulin stability. Int J Pharm 311: 1-10.
11. Rossetti P, Porcellati F, Fanelli CG, Perriello G, Torlone E, Bolli GB (2008) Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus. Arch Physiol Biochem 114: 3-10.
12. Carino GP, Mathiowitz E (1999) Oral insulin delivery. Adv Drug Deliv Rev 35: 249-257.
13. Patel N, Craddock BL, Staniforth JN, Tobyn MJ, Welham MJ (2001) Spray-dried insulin particles retain biological activity in rapid in-vitro assay. J Pharm Pharmacol 53: 1415-1418.
14. Heinemann L, Pfutzner A, Heise T (2001) Alternative routes of administration as an approach to improve insulin therapy: update on dermal, oral, nasal and pulmonary insulin delivery. Curr Pharm Des 7: 1327-1351.
15. Owens DR, Zinman B, Bolli G (2003) Alternative routes of insulin delivery. Diabet Med 20: 886-898.
16. Damge C, Reis CP, Maincent P (2008) Nanoparticle strategies for the oral delivery of insulin. Expert Opin Drug Deliv 5: 45-68.
17. Müller G (2010) Personalized prognosis and diagnosis of type 2 diabetes-vision or fiction? Pharmacology 85: 168-187.
18. Wong TW (2010) Design of oral insulin delivery systems. J Drug Target 18: 79-92.
19. Saffran M, Pansky B, Budd GC, Williams FE (1997) Insulin and the gastrointestinal tract. J Control Release 46: 89-98.
20. Mahato RI, Narang AS, Thoma L, Miller DD (2003) Emerging trends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst 20: 153-214.
21. Gomez-Orellana I (2005) Strategies to improve oral drug bioavailability. Expert Opin Drug Deliv 2: 419-433.
22. Allémann E, Leroux J, Gurny R (1998) Polymeric nano-and microparticles for the oral delivery of peptides and peptidomimetics. Adv Drug Deliv Rev 34: 171-189.
23. Delie F (1998) Evaluation of nano-and microparticle uptake by the gastrointestinal tract. Adv Drug Deliv Rev 34: 221-233.
24. Varum FJ, McConnell EL, Sousa JJ, Veiga F, Basit AW (2008) Mucoadhesion and the gastrointestinal tract. Crit Rev Ther Drug Carrier Syst 25: 207-258.
25. Babu VR, Patel P, Mundargi RC, Rangaswamy V, Aminabhavi TM (2008) Developments in polymeric devices for oral insulin delivery. Expert Opin Drug Deliv 5: 403-415.
26. Gholamipour-Shirazi A (2008) Insulin encapsulation. Expert Opin Drug Deliv 5: 1335-1355.
27. Ramesan RM, Sharma CP (2009) Challenges and advances in nanoparticle-based oral insulin delivery. Expert Rev Med Devices 6: 665-676.
28. Woitiski CB, Carvalho RA, Ribeiro AJ, Neufeld RJ, Veiga F (2008) Strategies toward the improved oral delivery of insulin nanoparticles via gastrointestinal uptake and translocation. BioDrugs 22: 223-237.
29. Chen MC, Sonaje K, Chen KJ, Sung HW (2011) A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery. Biomaterials 32: 9826-9838.
30. Lai SK, Wang Y-Y, Hanes J (2009) Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 61: 158-171.
31. Aprahamian M, Michel C, Humbert W, Devissaguet JP, Damge C (1987) Transmucosal passage of polyalkylcyanoacrylate nanocapsules as a new drug carrier in the small intestine. Biol Cell 61: 69-76.
32. Eldridge JH, Hammond CJ, Meulbroek JA, Staas JK, Gilley RM, Tice TR (1990) Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the peyer's patches. J Control Release 11: 205-214.
33. Hillaireau H, Couvreur P (2009) Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol Life Sci 66: 2873-2896.
34. Desai MP, Labhasetwar V, Amidon GL, Levy RJ (1996) Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm Res 13: 1838-1845.
35. Jung T, Kamm W, Breitenbach A, Hungerer K-D, Hundt E, Kissel T (2001) Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application inmice. Pharm Res 18: 352-360.
36. Florence AT (2005) Nanoparticle uptake by the oral route: fulfilling its potential? Drug Discov Today 2: 75-81.
37. des Rieux A, Fievez V, Theate I, Mast J, Preat V, Schneider YJ (2007) An improved in vitro model of human intestinal follicle-associated epithelium to study nanoparticle transport by M cells. Eur J Pharm Sci 30: 380-391.
38. des Rieux A, Fievez V, Garinot M, Schneider Y-J, Préat V (2006) Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release 116: 1-27.
39. Jani P, Halbert GW, Langridge J, Florence AT (1989) The uptake and translocation of latex nanospheres and microspheres after oral administration to rats. J Pharm Pharmacol 41: 809-812.
40. Shakweh M, Besnard M, Nicolas V, Fattal E (2005) Poly (lactide-co-glycolide) particles of different physicochemical properties and their uptake by peyer's patches in mice. Eur J Pharm Biopharm 61: 1-13.
41. Wang YY, Lai SK, Suk JS, Pace A, Cone R, Hanes J (2008) Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that "slip" through the human mucus barrier. Angew Chem Int Ed Engl 47: 9726-9729.
42. Tang BC, Dawson M, Lai SK, Wang YY, Suk JS, Yang M, Zeitlin P, Boyle MP, Fu J, Hanes J (2009) Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier. Proc Natl Acad Sci U S A 106: 19268-19273.
43. Smart JD (2005) The basics and underlying mechanisms of mucoadhesion. Adv Drug Deliv Rev 57: 1556-1568.
44. Pinto-Alphandary H, Aboubakar M, Jaillard D, Couvreur P, Vauthier C (2003) Visualization of insulin-loaded nanocapsules: in vitro and in vivo studies after oral administration to rats. Pharm Res 20: 1071-1084.
45. Dünnhaupt S, Barthelmes J, Hombach J, Sakloetsakun D, Arkhipova V, Bernkop-Schnürch A (2011) Distribution of thiolated mucoadhesive nanoparticles on intestinal mucosa. Int J Pharm 408: 191-199.
46. Khutoryanskiy VV (2011) Advances in mucoadhesion and mucoadhesive polymers. Macromol Biosci 11: 748-764.
47. Galloway JA, Chance RE (1994) Improving insulin therapy-achievements and challenges. Horm Metab Res 26: 591-598.
48. Pillai O, Panchagnula R (2001) Insulin therapies-past, present and future. Drug Discov Today 6: 1056-1061.
49. Müller G (2011) Novel applications for glycosylphosphatidylinositol-anchored proteins in pharmaceutical and industrial biotechnology. Mol Membr Biol 28: 187-205.
50. Roger E, Lagarce F, Garcion E, Benoit JP (2010) Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. Nanomedicine (Lond) 5: 287-306.
51. Shakweh M, Ponchel G, Fattal E (2004) Particle uptake by Peyer's patches: a pathway for drug and vaccine delivery. Expert Opin Drug Deliv 1: 141-163.
52. Hussain N, Jani PU, Florence AT (1997) Enhanced oral uptake of tomato lectin-conjugated nanoparticles in the rat. Pharm Res 14: 613-618.
53. Russell-Jones GJ (2004) Use of targeting agents to increase uptake and localization of drugs to the intestinal epithelium. J Drug Target 12: 113-123.
54. Weissenboeck A, Bogner E, Wirth M, Gabor F (2004) Binding and uptake of wheat germ agglutinin-grafted PLGA-nanospheres by Caco-2 monolayers. Pharm Res 21: 1917-1923.
55. Lochner N, Lobmaier C, Wirth M, Leitner A, Pittner F, Gabor F (2003) Silver nanoparticle enhanced immunoassays: one step real time kinetic assay for insulin in serum. Eur J Pharm Biopharm 56: 469-477.
56. Petrus A, Vortherms A, Fairchild T, Doyle R (2007) Vitamin B12 as a carrier for the oral delivery of insulin. ChemMedChem 2: 1717-1721.
57. Chalasani K, Russell-Jones G, Jain A, Diwan P, Jain S (2007) Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles. J Control Release 122: 141-150.
58. McEwan JF, Veitch HS, Russell-Jones GJ (1999) Synthesis and biological activity of ribose-50-carbamate derivatives of vitamin B12. Bioconjug Chem 10: 1131-1136.
59. Chalasani KB, Russell-Jones GJ, Yandrapu SK, Diwan PV, Jain SK (2007) A novel vitamin B12-nanosphere conjugate carrier system for peroral delivery of insulin. J Control Release 117: 421-429.
60. Lochner N, Pittner F, Wirth M, Gabor F (2003) Wheat germ agglutinin binds to the epidermal growth factor receptor of artificial Caco-2 membranes as detected by silver nanoparticle enhanced fluorescence. Pharm Res 20: 833-839.
61. Orlean P, Menon AK (2007) Thematic review series: lipid posttranslational modifications. GPI anchoring of protein in yeast and mammalian cells, or: how we learned to stop worrying and love glycophospholipids. J Lipid Res 48: 993-1011.
62. Pappenheimer JR (1987) Physiological regulation of transepithelial impedance in the intestinal mucosa of rats and hamsters. J Membr Biol 100: 137-148.
63. Nellans HN (1991) Mechanisms of peptide and protein absorption. 1. Paracellular intestinal transport-modulation of absorption. Adv Drug Deliv Rev 7: 339-364.
64. Salamat-Miller N, Johnston TP (2005) Current strategies used to enhance the paracellular transport of therapeutic polypeptides across the intestinal epithelium. Int J Pharm 294: 201-216.
65. Plapied L, Duhem N, des Rieux A, Préat V (2011) Fate of polymeric nanocarriers for oral drug delivery. Curr Opin Colloid Interface Sci 16: 228-237.
66. Mi FL, Wu YY, Lin YH, Sonaje K, Ho YC, Chen CT, Juang JH, Sung HW (2008) Oral delivery of peptide drugs using nanoparticles self-assembled by poly(gamma-glutamic acid) and a chitosan derivative functionalized by trimethylation. Bioconjug Chem 19: 1248-1255.
67. Lin YH, Sonaje K, Lin KM, Juang JH, Mi FL, Yang HW, Sung HW (2008) Multi-ioncrosslinked nanoparticles with pH-responsive characteristics for oral delivery of protein drugs. J Control Release 132: 141-149.
68. Cheng WP, Gray AI, Tetley L, Hang Tle B, Schatzlein AG, Uchegbu IF (2006) Polyelectrolyte nanoparticles with high drug loading enhance the oral uptake of hydrophobic compounds. Biomacromolecules 7: 1509-1520.
69. Jevprasesphant R, Penny J, Attwood D, McKeown NB, D'Emanuele A (2003) Engineering of dendrimer surfaces to enhance transepithelial transport and reduce cytotoxicity. Pharm Res 20: 1543-1550.
70. Bayat A, Dorkoosh FA, Dehpour AR, Moezi L, Larijani B, Junginger HE, Rafiee-Tehrani M (2008) Nanoparticles of quaternized chitosan derivatives as a carrier for colon delivery of insulin: ex vivo and in vivo studies. Int J Pharm 356: 259-266.
71. Sadeghi AM, Dorkoosh FA, Avadi MR, Weinhold M, Bayat A, Delie F, Gurny R, Larijani B, Rafiee-Tehrani M, Junginger HE (2008) Permeation enhancer effect of chitosan and chitosan derivatives: comparison of formulations as soluble polymers and nanoparticulate systems on insulin absorption in Caco-2 cells. Eur J Pharm Biopharm 70: 270-278.
72. Thanou M, Verhoef JC, Junginger HE (2001) Oral drug absorption enhancement by chitosan and its derivatives. Adv Drug Deliv Rev 52: 117-126.
73. Artursson P, Lindmark T, Davis SS, Illum L (1994) Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res 11: 1358-1361.
74. Kotzé AF, de Leeuw BJ, Lueßen HL, de Boer AG, Verhoef JC, Junginger HE (1997) Chitosans for enhanced delivery of therapeutic peptides across intestinal epithelia: in vitro evaluation in Caco-2 cell monolayers. Int J Pharm 159: 243-253.
75. van der Lubben IM, Verhoef JC, Borchard G, Junginger HE (2001) Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur J Pharm Sci 14: 201-207.
76. Ranaldi G, Marigliano I, Vespignani I, Perozzi G, Sambuy Y (2002) The effect of chitosan and other polycations on tight junction permeability in the human intestinal Caco-2 cell line. J Nutr Biochem 13: 157-167.
77. Thanou MM, Kotzé AF, Scharringhausen T, Luessen HL, de Boer AG, Verhoef JC, Junginger HE (2000) Effect of degree of quaternization of N-trimethyl chitosan chloride for enhanced transport of hydrophilic compounds across intestinal Caco-2 cell monolayers. J Control Release 64: 15-25.
78. Thompson C, Cheng W, Gadad P, Skene K, Smith M, Smith G, McKinnon A, Knott R (2011) Uptake and transport of novel amphiphilic polyelectrolyte-insulin nanocomplexes by Caco-2 cells-towards oral insulin. Pharm Res 28: 886-896.
79. Thompson CJ, Tetley L, Uchegbu IF, Cheng WP (2009) The complexation between novel comb shaped amphiphilic polyallylamine and insulin-towards oral insulin delivery. Int J Pharm 376: 46-55.
80. Woitiski CB, Sarmento B, Carvalho RA, Neufeld RJ, Veiga F (2011) Facilitated nanoscale delivery of insulin across intestinal membrane models. Int J Pharm 412: 123-131.